The fact that it took five trades to accumulate 500 measly shares tells us all anyone needs to know. There are very few shares available at the price. And yet the stock price is down. Two logically inconsistent facts that essentially prove manipulation. At least for those who choose to employ logic.

Not one thing in your list of supposed missteps do I blame management for. That's a whole lot of red herrings in my book. Which is why Adage doesn't care, and has been happy to hold without a peep.

FBG, Adage has given no indication of having any displeasure with ADXS's progress, or with management. What would they be upset about? Everything is going great with the trials, EU application coming, etc. You are talking about the world's most astute investors here. If you think they don't understand the stock manipulation game, and that they care about anything other than the science, you are mistaken. If they wanted a change, they would simply pick up a phone . . .

Cool, good for you, Cyber. I suspect you will be the lone I-Hub representative. The board would like you to ask Dan why he's such a greedy jerk who can't be bothered to control the share price a little better. Also, does Aratana have any employees?

Yeah, I think there's a quiet period for a proxy vote.

Very coy, James. Do you have a specific development in mind that will require the services of a corporate investor relations representative?

James, I assume it would be pointless to ask you to explain?

FBG, for a smart guy the fact that you can't recognize that this is all manipulation surprises me. When a stock acts contrary to the facts, there you have it. Instead, you start looking for non-existent facts to justify the stock action.

Good for you, Billy. Your approach is 100% the right one. When a stock is unfairly priced don't complain about it. Take advantage of it. Have faith in your opinion of the company and don't look for baseless reasons to question it. That, and a little patience and conviction, is what makes people rich.

On some it works, Bourbon. Mainly those who do not have courage in their convictions. If you think you are correct about ADXS, people should suck it up and be patient, and don't allow their emotions to be manipulated. It really frustrates me to see people fall for it and, not only that, try to recruit others to their emotional outlook.

There is one reason, and one reason only, Batermere, that ADXS seems to go down for no reason, and even defies the sector, and even defies GOOD news quite often. It is because it is the most manipulated stock in the biotech sector. Quite simply, they are trying to convince you that nothing ADXS ever does will ever matter to the share price. Which is false, but that doesn't stop them from trying.

The longs' management bashing, hysteria, and incessant griping about the manipulated pps encourages the short cabal big time. They view you as weak longs who may give up. Playing right into their hands. But please, continue with your campaign to attribute the suppressed share price to management, despite a lack of logic and valid arguments. It will not result in anything other than encouraging the people who are really responsible for the share price, but so be it.

There will be no discussion of any increased management compensation. Authorizing a pool of options because it needed to be renewed is not the granting of compensation.

Lol. Based on what? Ever hear about ASCO? Submitting the EMA application? Probable deal for AXAL in the EU? Combo trial data update? Aratana FDA approval? You should really try to disguise the fact that you are trying to trade now. Although your previous pumping when you were long was not much better.

A deal doesn't have to happen tomorrow. It just has to happen. And no option grant will occur tomorrow either. Not sure where that comes from.

You mean the Astra combo? It does make sense. Although I'm not sure there is a "hold up." Give them time. It is coming.

I was thinking strictly of the impact on the pps if they wait until the application is submitted. I don't think they will wait, just trying to think of any plausible scenario for doing so.

Of course a deal for EU is coming. It's a matter of when, not if. It's in the milestones, same as the deal for NEO was predicted. As you have pointed out, they have to prepare for the possibility of commercialization coming rather quickly after the application. The only reason I can think of to delay it slightly would be to wait until the EMA application is submitted, to get better terms (share price for the equity aspect of the deal). Which I suspect (hope) they are working on with all due speed. However, I doubt they will wait for that.

They gave the robots the day off Friday and today. Goes to show you how much of the trading is phony. Volume is really anemic.

It amazes me that anyone would take the time to understand how promising ADXS's treatments are, hold the stock through these months of rampant manipulation, and then sell just as it's getting interesting. Makes me wonder why someone would invest in biotech in the first place. None of this is unique to ADXS. It is a sector characterized by typical delays and rampant manipulation. To anyone who sells now, the shorts say "thank you for playing . . ."

Thanks, James.

I wish we could get an update on the enrollment progress for Phase 3. Maybe at the shareholders' meeting.

Not to mention that an EU partner could possibly start generating revenue if ADXS receives conditional approval.

I, also, doubt DOC would license U.S. rights now. He has always had extreme confidence in the platform and, thus, he clearly has had a natural bias in favor of front-end dilution instead of back-end. I believe the only reason he will even license EU is because: (1) he will take the working capital; (2) he recognizes that he needs to garner some validation from BP on an advanced indication (as opposed to the pre-clinical NEO); and (3) he has to get his marketing/distribution ducks in a row due to the speed at which the EMA process is moving.

Me too, and I'll take that additional $100m in an upfront licensing payment.

52-week high is not the only metric. Both ADRO and ZIOP are down around 75% from their highs a couple of years ago, similar to ADXS. And my point is that comparing ADXS's percentage of 52-week high to IBB or XBI's 5% does not tell the whole story. Every single clinical biotech I follow (7-8 stocks) have been similarly pummeled as ADXS.

Excellent job, Hovacre. Thank you.

Forget the IBB. Look at ADRO, ZIOP and virtually every other clinical biotech. All suffering the same.

A CEO's job is to promote long term shareholder. In biotech that means funding and drug development. They are doing both. If this was a mature company whose pps is based on metrics for which the CEO is responsible, then blame the CEO. ADXS's pps is currently based on the actions of a manipulation cartel.

A CEO is not a hedge fund who only gets paid a percentage of stock profits. A CEO is paid to manage the company and progress drug development, which he has done. That is all a CEO can do. The share price does not correlate to the progress. Biotech stock values are all over the map, and are very subjective and manipulated.

Great find, Tex. You could take that language and substitute "AXAL" for ""Keytruda" and very easily envision that result as a future PR.

Gaji, the EMA certification of the production facility was last week. The full application is expected in 2nd half 2017. This board's most knowledgeable "medicine" person ( Hovacre, imo) believes that conditional EMA approval is a reasonable possibility.

ADRO, ZIOP, etc. all up nicely today. And IBB and XBI. Although ADXS is up more.

Yeah, that was a completely different biotech market two years ago, Batermere. That was a market in which traders AND investors were optimistic and speculating. People were buying "promise" and weren't requiring much else. The tone now is the opposite. Now even very promising companies that are showing great results and are positioned well are being attacked for no real reason. Same company, different trading/investing bias. Better company now, actually. The cycle will complete itself, hopefully soon, but I will wait as long as it takes. Patience is the one thing they cannot take from you, and it is the only weapon retail investors like us can wield against the market manipulators.

DOC is to blame for a baseless FDA hold and an inefficient FDA approval of the SPA? He is to blame for PETX turning out to be incompetent as well as Biocon, a very large asian pharma? At the time of those deals ADXS had alot of prestige and bargaining leverage? It was a virtual unknown, on the balls of its arse.

I'm fairly sure that virtually all of those other young biotechs have also raised money with offerings and issued options to management.

FBG, you agree that the stock is woefully undervalued. Therefore, management has created more value than is reflected in the pps. Otherwise it would be fairly valued.

It was true then and it's true now: management does not control the stock price. There are overvalued stocks and undervalued ones. ADXS is the latter. Simple as that.

A wonderful story, and I am very happen for Ms. Frazier. It amazes me that there are people who would actively try to harm a company that is doing such good things for people.

Fraudfighter, not a single ADXS patient has become virulent from the attenuated Listeria. I am sure that medical professionals and biotech analysts are able to understand this. You are way off on this one if you think anyone with a brain believes this is a significant risk.